Health. Sanofi: Doliprane officially passes under the American flag
Pharmaceutical giant Sanofi has officially sold 50% of its subsidiary Opella, which produces Doliprane, to the American fund CD&R.
Doliprane is the most prescribed medication in France. Illustrative photo Sipa / Adil Benayache
Doliprane, the most prescribed drug in France, is officially coming under American control, with the finalization on Wednesday of Sanofi's sale of control of the company that produces the popular yellow box to the investment fund CD&R.
"It's official: Opella is now an independent company": the completion of this transaction, the announcement of which in October sparked a backlash from politicians and unions, was confirmed just before the pharmaceutical giant's general meeting of shareholders on Wednesday afternoon in Paris.
“Doliprane will remain in France for the French”Sanofi is selling 50% of its Opella subsidiary, which notably produces Doliprane, to the American fund CD&R, while retaining a 48.2% stake in this company which markets over-the-counter treatments and vitamins, minerals and supplements.
"This change in shareholders changes nothing: Doliprane will remain in France for the French," assured Opella CEO Julie Van Ongevalle during the general meeting at the Palais des Congrès, located at Porte Maillot.
"With the commitments made in terms of social issues, employment, and investment, we have taken all parties into account," stated the chairman of the board of directors of Sanofi, former banker Frédéric Oudéa.
Le Bien Public
